Across TCGA pan-cancer cohorts, IRAK4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IRAK4 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher IRAK4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IRAK4 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, LSCC, and HNSC are the cancer types where IRAK4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.448	1.000	.002	38	view →
LSCC	DFS	Median	All	0.991	0.888	.006	7	view →
HNSC	DFS	Median	All	0.557	0.741	.018	6	view →
GBM	DFS	Quartile	All	0.259	0.424	.015	5	view →
LUAD	OS	Tertile	All	0.595	0.919	.031	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: IRAK4 tumor-vs-normal RNA expression · all IRAK4 data types